Table 3:

Secondary efficacy outcomes and safety analysis by age group

	Children (aged <18 years)			Adults (aged 18–65 years)			Older adults (aged >65 years)
	Levetiracetam	Fosphenytoin	Valproate	Levetiracetam	Fosphenytoin	Valproate	Levetiracetam	Fosphenytoin	Valproate
ITT population	85	71	69	71	54	61	19	17	15
Admission to ICU	53 (62%)	45 (63%)	43 (62%)	38 (54%)	26 (48%)	34 (56%)	15 (79%)	13 (76%)	8 (53%)
Length of ICU stay, days	1 (0–2)	1 (0–2)	1 (0–2)	1 (0–3)	0 (0–3)	1 (0–3)	3 (1–6)	2 (1–7)	2 (0–6)
Length of hospital stay, days	2 (1–3)	2 (1–3)	2 (1–4)	3 (1–6)	3 (1–7)	2 (1–6)	7 (5–12)	5 (3–16)	5 (3–16)
Safety population	86	73	70	74	58	64	20	18	15
Life-threatening hypotension within 60 min of start of study drug infusion	0	2 (3%)	3 (4%)	0	2 (3%)	0	1 (5%)	1 (6%)	0
Life-threatening cardiac arrhythmia within 60 min of start of study drug infusion	0	0	0	1 (1%)	0	0	0	0	0
Acute respiratory depression	5 (6%)	13 (18%)	7 (10%)	10 (14%)	6 (10%)	5 (8%)	0	2 (11%)	0
Endotracheal intubation within 60 min of start of study drug infusion	7 (8%)	24 (33%)	8 (11%)	19 (26%)	13 (22%)	14 (22%)	7 (35%)	5 (28%)	2 (13%)
Acute seizure recurrence 60 min-12 h after start of study drug infusion	8 (9%)	11 (15%)	6 (9%)	5 (7%)	3 (5%)	5 (8%)	4 (20%)	4 (22%)	3 (20%)
Death	1 (1%)	0	1 (1%)	2 (3%)	2 (3%)	1 (2%)	4 (20%)	1 (6%)	0

Data are n, n (%), or median (IQR). No patients had anaphylaxis or purple glove syndrome. ITT=intention-to-treat. ICU=intensive care unit.